Korro Bio, Inc., a Cambridge, Mass.-based provider of a platform for RNA editing to modulate protein function for therapeutic applications, raised $91.5m in Series A financing.
The round was led by Wu Capital with participation from current investors, Atlas Venture and New Enterprise Associates. Additional new investors include Qiming Venture Partners USA, Surveyor Capital (a Citadel company), Cormorant Asset Management, MP Healthcare Venture Management and Alexandria Venture Investments.
The company intends to use the funds to advance its lead program to IND filing and establish a broad portfolio of innovative RNA editing therapies.
Founded in 2018 by Nessan Bermingham, Ph.D., executive chair, Korro provides a proprietary platform, OPERA (Oligonucleotide Promoted Editing of RNA), which harnesses the body’s natural base editing system — specifically ADAR (Adenosine Deaminase Acting on RNA) — to make targeted edits to a single RNA base. OPERA can repair disease-causing mutations at the RNA level, in addition to creating therapeutically beneficial versions of proteins to improve patient outcomes.